Drugs / FLD-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07670858 | Oct 2024 → Feb 2027 expected | nodular basal cell carcinoma | Feldan Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-31 | Feldan Therapeutics | FELDAN THERAPEUTICS ANNOUNCES THE TREATMENT OF THE FIRST PATIENT IN THE PHASE 1/2A CLINICAL TRIAL OF ITS CANDIDATE FLD-103, AGAINST BASAL CELL CARCINOMA feldan.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLD-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07670858 ↗ |
| Route | Other | “Intralesional and perilesional injection of FLD-103” NCT07670858 ↗ |